肝癌切除术后预后预测的研究进展

doi:10.3969/j.issn.1009-976X.2021.04.021

摘要/Abstract

摘要： 肝癌是消化系统最常见的恶性肿瘤类型之一,手术切除是治疗肝癌的重要方法。但是,肝癌的生物学特性决定了根治性切除术后仍存在较高的转移复发率,导致患者预后不佳。因此,探索并筛选肝癌切除术后预后预测的相关因素,将有助于为手术方案的制定和术后辅助治疗措施的选择提供更全面的参考依据。本综述将从肿瘤分期系统、免疫炎症相关指标、血清肿瘤标记物、非编码RNA、肝功能、影像学特征和临床模型等方面,对肝癌切除术后预后预测的研究进展做一综述。

关键词: 肝癌, 肝切除术, 预后, 预测因素

Abstract: Hepatocellular carcinoma （HCC） is one of the most common malignant neoplasms in the digestive system and surgical resection is an important method to treat HCC. However, the biological characteristics of HCC determine that there is still a high rate of metastasis and recurrence after radical resection,which finally leads to poor prognosis. Therefore, exploring the prognostic predictive factors for HCC after liver resection will be helpful to provide a more comprehensive reference for the formulation of surgical plans and the selection of postoperative adjuvant treatment measures. This article will review the relevant progress of prognosis prediction of HCC after liver resection from the aspects of tumor staging system, immune-inflammation-related indicators, serum tumor markers, non-coding RNA, liver function, imaging features and clinical models.

Key words: hepatocellular carcinoma, hepatectomy, prognosis, predictive factors

中图分类号:

R735.7

王庆斌, 商昌珍, 陈亚进. 肝癌切除术后预后预测的研究进展[J]. 岭南现代临床外科, 2021, 21(04): 471-476.

WANG Qing-bin, SHANG Chang-zhen, CHEN Ya-jin. Progress on the prognosis prediction of hepatocellular carcinoma after liver resection[J]. Lingnan Modern Clinics In Surgery, 2021, 21(04): 471-476.

参考文献

[1] Bray F, Ferlay J, Soerjomataram I, et al.Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA: A Cancer J Clin, 2018,68(6):394-424.
[2] Tabrizian P, Jibara G, Shrager B, et al.Recurrence of Hepatocellular Cancer After Resection[J]. Ann Surg, 2015,261(5):947-955.
[3] Tellapuri S, Sutphin PD, Beg MS, et al.Staging systems of hepatocellular carcinoma: A review[J]. Indian J Gastroenterol, 2018,37(6):481-491.
[4] Torzilli G, Belghiti J, Kokudo N, et al.A snapshot of the effective indications and results of surgery for hepatocellular carcinoma in tertiary referral centers: is it adherent to the EASL/AASLD recommendations?: an observational study of the HCC East-West study group[J]. Ann Surg, 2013,257(5):929-937.
[5] 中华人民共和国卫生和计划生育委员会医政医管局.原发性肝癌诊疗规范(2017年版)[J].中华消化外科杂志,2017,16(7):635-647.
[6] 中华人民共和国国家卫生健康委员会医政医管局. 原发性肝癌诊疗规范(2019年版)[J]. 中国实用外科杂志, 2020, 40(2):121-138.
[7] Li Y, Qiu S, Fan J, et al.Intratumoral neutrophils: A poor prognostic factor for hepatocellular carcinoma following resection[J]. J Hepatol, 2011,54(3):497-505.
[8] Shu QH, Ge YS, Ma HX, et al.Prognostic value of polarized macrophages in patients with hepatocellular carcinoma after curative resection[J]. J Cell Mol Med, 2016,20(6):1024-1035.
[9] Huang Y, Wang F, Wang Y, et al.Intrahepatic interleukin-17+ T cells and FoxP3+ regulatory T cells cooperate to promote development and affect the prognosis of hepatocellular carcinoma[J]. J Gastroenterol Hepatol, 2014,29(4):851-859.
[10] Zhou Z, Xin H, Li J, et al.Intratumoral plasmacytoid dendritic cells as a poor prognostic factor for hepatocellular carcinoma following curative resection[J]. Cancer Immunol Immunother, 2019,68(8):1223-1233.
[11] Noda Y, Kawaguchi T, Korenaga M, et al.High serum interleukin-34 level is a predictor of poor prognosis in patients with non-viral hepatocellular carcinoma[J]. Hepatol Res, 2019,49(9):1046-1053.
[12] Shi J, Wang Y, Wang F, et al.Interleukin 22 is related to development and poor prognosis of hepatocellular carcinoma[J]. Clin Res Hepatol Gastroenteroly, 2020,44(6):855-864.
[13] Li L, Zhu Y H, Li Y, et al.Identification of chemokine CXCL10 in tumor microenvironment by antibody array as a prognostic marker in hepatocellular carcinoma[J]. Neoplasma, 2017,64(05):778-786.
[14] Budhu A, Forgues M, Ye Q, et al.Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment[J]. Cancer Cell, 2006,10(2):99-111.
[15] Wang Z, Zhu J, Liu Y, et al.Development and validation of a novel immune-related prognostic model in hepatocellular carcinoma[J]. J Transl Med, 2020,18(1):67.
[16] 彭颖, 龚光辉, 李景和, 等. 基于免疫相关基因标签的原发性肝癌预后评分系统的建立[J]. 中国普通外科杂志, 2020,29(2):179-189.
[17] 吴晓龙, 毕新宇, 李智宇, 等. 术后中性粒细胞和淋巴细胞比值与肝细胞癌切除术后复发及患者生存的关系[J]. 中华肿瘤杂志,2018,40(5): 365-371.
[18] Yamamura K, Sugimoto H, Kanda M, et al.Comparison of inflammation-based prognostic scores as predictors of tumor recurrence in patients with hepatocellular carcinoma after curative resection[J]. J Hepatobiliary Pancreat Sci, 2014,21(9):682-688.
[19] Wang B, Tian L, Gao X, et al.Dynamic change of the systemic immune inflammation index predicts the prognosis of patients with hepatocellular carcinoma after curative resection[J]. Clin Chem Lab Med, 2016,54(12):1963-1969.
[20] Xu Q, Yan Y, Gu S, et al.A Novel Inflammation-Based Prognostic Score: The Fibrinogen/Albumin Ratio Predicts Prognoses of Patients after Curative Resection for Hepatocellular Carcinoma[J]. J Immunol Res, 2018,2018:4925498.
[21] Sharma Y, Weaver MJ, Ludwig DR, et al.Serum alpha-fetoprotein level per total tumor volume as a predictor of recurrence of hepatocellular carcinoma after resection[J]. Surgery, 2018,163(5):1002-1007.
[22] Li X, Zhu X, Cai H, et al.Postoperative α-fetoprotein response predicts tumor recurrence and survival after hepatectomy for hepatocellular carcinoma: A propensity score matching analysis[J]. Surgery, 2019,165(6):1161-1167.
[23] Cheng J, Wang W, Zhang Y, et al.Prognostic Role of Pre-Treatment Serum AFP-L3% in Hepatocellular Carcinoma: Systematic Review and Meta-Analysis[J]. PLoS ONE, 2014,9(1):e87011.
[24] Meguro M.Prognostic roles of preoperative α-fetoprotein and des-γ-carboxy prothrombin in hepatocellular carcinoma patients[J]. World J Gastroenterol, 2015,21(16):4933.
[25] Okamura Y, Sugiura T, Ito T, et al.The Half-Life of Serum Des-Gamma-Carboxy Prothrombin Is a Prognostic Index of Survival and Recurrence After Liver Resection for Hepatocellular Carcinoma[J]. Ann Surg Oncol, 2016, 23(Suppl 5):921-928.
[26] Huang Y, Zeng J, Liu T, et al.Prognostic Significance of Elevated Preoperative Serum CA125 Levels After Curative Hepatectomy for Hepatocellular Carcinoma[J]. Onco Targets Ther, 2020,13:4559-4567.
[27] Nagy Á, Lánczky A, Menyhárt O, et al.Validation of miRNA prognostic power in hepatocellular carcinoma using expression data of independent datasets[J]. Sci Rep, 2018,8(1):9227.
[28] Zhu S, Huang X, Zhang K, et al.Low expression of long noncoding RNA CTC-297N7.9 predicts poor prognosis in patients with hepatocellular carcinoma[J]. Cancer Med, 2019,8(18):7679-7692.
[29] Zhao Q, Zhang J, Xu L, et al.Identification of a five-long non-coding RNA signature to improve the prognosis prediction for patients with hepatocellular carcinoma[J]. World J Gastroenterol, 2018,24(30):3426-3439.
[30] Long J, Bai Y, Yang X, et al.Construction and comprehensive analysis of a ceRNA network to reveal potential prognostic biomarkers for hepatocellular carcinoma[J]. Cancer Cell Int, 2019,19:90.
[31] Li Y, Ma B, Yin Z, et al.Competing endogenous RNA network and prognostic nomograms for hepatocellular carcinoma patients who underwent R0 resection[J]. J Cell Physiol, 2019,234(11):20342-20353.
[32] Liu P, Hsu C, Hsia C, et al.Prognosis of hepatocellular carcinoma: Assessment of eleven staging systems[J]. J Hepatol, 2016,64(3):601-608.
[33] Wang YY, Zhong JH, Su ZY, et al.Albumin-bilirubin versus Child-Pugh score as a predictor of outcome after liver resection for hepatocellular carcinoma[J]. Br J Surg, 2016,103(6):725-734.
[34] Chan AWH, Kumada T, Toyoda H, et al.Integration of albumin-bilirubin (ALBI) score into Barcelona Clinic Liver Cancer (BCLC) system for hepatocellular carcinoma[J]. J Gastroenterol Hepatol, 2016,31(7):1300-1306.
[35] Ho S, Liu P, Hsu C, et al.Comparison of twelve liver functional reserve models for outcome prediction in patients with hepatocellular carcinoma undergoing surgical resection[J]. Sci Rep, 2018,8(1):4710-4773.
[36] 文夏杰,姚明解,张玲,等. 实验室常见检测指标对肝细胞癌预后预测价值的思考[J]. 临床肝胆病杂志,2018,34(7):1395-1398.
[37] Li J,Xu X,Han J,et al.Preoperative prealbumin level as an independent predictor of long-term prognosis after liver resec-tion for hepatocellular carcinoma:a multi - institutional study[J]. HPB(Oxford,England),2019,21(2):157-166.
[38] An C,Kim DW,Park Y,et al.Single Hepatocellular Carcino-ma:Preoperative MR Imaging to Predict Early Recurrence after Curative Resection[J]. Radiology,2015,276(2):433-443.
[39] Lee JW,Hwang SH,Kim HJ,et al.Volumetric parameters on FDG PET can predict early intrahepatic recurrence-free survival in patients with hepatocellular carcinoma after curative surgical resection[J]. Eur J Nucl Med Mol Imaging,2017,44(12):1984-1994.
[40] Brenet Defour L,Mulé S,Tenenhaus A,et al.Hepatocellular carcinoma:CT texture analysis as a predictor of survival after surgical resection[J]. Eur Radiol,2019,29(3):1231-1239.
[41] Lee S,Kim SH,Hwang JA,et al.Pre-operative ADC predicts early recurrence of HCC after curative resection[J]. Eur Radi-ol,2019,29(2):1003-1012.
[42] Zhang Y,Kuang S,Shan Q,et al.Can IVIM help predict HCC recurrence after hepatectomy?[J]. Eur Radiol,2019,29(11):5791-5803.
[43] Pan YX,Chen JC,Fang AP,et al.A nomogram predicting the recurrence of hepatocellular carcinoma in patients after laparo-scopic hepatectomy[J]. Cancer Commun(Lond),2019,39(1):55.
[44] Ji GW,Zhu FP,Xu Q,et al.Machine-learning analysis of con-trast-enhanced CT radiomics predicts recurrence of hepatocellu-lar carcinoma after resection:A multi-institutional study[J].EBioMedicine,2019,50:156-165.